Our initial focus is on developing novel IO therapeutics targeting BTN(L)s to treat a range of solid tumors and hematologic cancers. Our programs were initially centered around the powerful mechanisms of action of γ9δ2 T cells, however, as our understanding of the BTN(L) biology has evolved we have utilized this knowledge to generate intellectual property around targeting other immune cell populations to create a diversified IO pipeline.
In parallel to advancing our IO programs, ImCheck is designing inhibitory mAbs that can diminish the dysfunctional immune system activation in autoimmune diseases. The company will remain strategic in our selection of programs to advance in-house and those we will consider for partnering.
